Inducible CreER/Temporally Controlled Knockout Model

  • Principle
  • Experimental Materials
  • Experimental Procedure
  • Troubleshooting

Materials Required

• Tamoxifen (HY-13757A)

Principle

The inducible CreER/CreERT2 system is based on a fusion between Cre recombinase and a modified estrogen receptor ligand-binding domain that retains Cre in the cytoplasm under basal conditions and allows nuclear translocation upon tamoxifen binding, enabling temporal control of site-specific recombination at loxP-flanked genomic loci in vivo or in vitro. Upon tamoxifen administration, CreER translocates to the nucleus and catalyzes recombination between loxP sites, resulting in excision or inversion of floxed DNA segments and enabling temporally defined gene knockout in specific tissues depending on promoter-driven CreER expression. This system has been widely used for inducible gene deletion and lineage tracing in mice, including validation of efficient temporal recombination in developmental and adult tissues using tamoxifen induction paradigms[1][2][3].

MCE has not independently verified the accuracy of these methods. They are for reference only.

Experimental Materials

• Tamoxifen is used as the ligand to activate CreER nuclear translocation and induce recombination in vivo or in cultured systems.
• It is typically prepared as a stock solution in oil-based solvents for systemic administration in mouse models[1][2].

• Corn oil or similar vehicles are used as solvent carriers for tamoxifen delivery in animal studies to ensure bioavailability and consistent dosing[1].

• Reporter alleles such as loxP-stop-loxP (LSL)-lacZ or fluorescent reporter systems are used to detect Cre-mediated recombination events via enzymatic activity or fluorescence readouts[2][3].

• PCR genotyping reagents are used to detect recombined alleles at the genomic DNA level following Cre activation[1][3].

• Standard animal injection equipment (e.g., intraperitoneal injection syringes) is used for systemic tamoxifen delivery in mouse models[1].

• Thermal cyclers are used for PCR-based recombination detection of floxed and recombined alleles[3].

• Fluorescence or histological imaging systems are used to visualize reporter activation in tissues following Cre-mediated recombination[2][3].

Experimental Procedure

• CreER-expressing mouse lines are bred with floxed target gene mice or reporter strains to generate experimental cohorts carrying both the inducible recombinase and loxP-flanked alleles, enabling temporal gene deletion upon tamoxifen administration[1][3].

• Tamoxifen is prepared in a hydrophobic solvent such as corn oil prior to administration to ensure stable delivery in vivo[1].

• Experimental animals are typically grouped into tamoxifen-treated and untreated controls to assess recombination specificity and baseline leakiness[2].

• Tamoxifen is administered systemically, commonly via intraperitoneal injection, to activate CreER-mediated recombination in adult or developing mice in a time-controlled manner[1][2].

• Following administration, CreER translocates to the nucleus in target cells and catalyzes recombination at loxP sites, resulting in permanent gene knockout or reporter activation in recombined cells[1][3].

• Recombination efficiency is assessed after an appropriate post-induction interval using tissue collection followed by PCR-based genotyping or reporter detection in histological sections[2][3].

• Successful recombination is determined by the presence of recombined alleles detected by PCR or by activation of reporter gene expression in target tissues[2][3].

• Negative controls include vehicle-treated CreER-positive animals and tamoxifen-treated Cre-negative animals to assess background recombination and specificity[1][2].

• Quantification of recombination efficiency is commonly performed by measuring the proportion of reporter-positive cells in tissue sections or by densitometric analysis of PCR bands representing recombined alleles[2][3].

Troubleshooting

Problem 1: Low recombination efficiency

Problem: Insufficient Cre-mediated recombination after tamoxifen induction.

Possible Cause

Low tamoxifen bioavailability or suboptimal CreER expression levels in target tissue.

Literature-supported Solution

Increasing tamoxifen exposure and confirming tissue-specific CreER expression improves recombination efficiency, as demonstrated in inducible CreER systems used in developmental and adult tissues[1][2].

Problem 2: Background recombination in untreated controls

Problem: Detectable recombination in the absence of tamoxifen.

Possible Cause

Ligand-independent basal activity (“leakiness”) of CreER fusion protein.

Literature-supported Solution

Use of optimized CreERT2 variants reduces basal recombination and improves temporal control fidelity[3].

Problem 3: Mosaic recombination in target tissue

Problem: Incomplete or heterogeneous recombination across target cells.

Possible Cause

Variable tamoxifen penetration and differential CreER expression across cell populations.

Literature-supported Solution

Temporal optimization of tamoxifen dosing and use of well-characterized CreER driver lines improve recombination uniformity in lineage-tracing studies[2][3].

Problem 4: Delayed recombination detection

Problem: Slow or weak reporter activation after induction.

Possible Cause

Time-dependent accumulation of reporter protein or delayed recombination kinetics.

Literature-supported Solution

Allow sufficient post-induction time before tissue collection, as recombination and reporter expression kinetics vary depending on tissue type and promoter activity[2].

Share